DESTINY-Breast04: practice-changing results for HER2-low breast cancer

Reflections on the DESTINY-Breast04 trial | Patricia LoRusso

DESTINY-Breast04: A ground-breaking trial in HER2-low breast cancer

DESTINY-Breast04: T-DXd for patients with HER2-low mBC

ASCO Daily News 2022 Plenary Update - LBA3: DESTINY-Breast04

Patient-reported outcomes from DESTINY-Breast04

ASCO2022 DESTINY BREAST 04 - How can we interpret a trial without pre or post treatment information?

DESTINY-Breast04: T-DXd provides significant improvement in OS + PFS in HER2-low mBC

Detailed safety analysis from the DESTINY-Breast04 trial

ASCO 2022: DESTINY-Breast04, PALOMA-2, rEECur

Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer pts

DESTINY-Breast04 Study Discussion - OncBrothers (Rohit and Rahul Gosain) with Dr. Shanu Modi

Updated results of DESTINY-Breast03: T-DXd vs T-DM1 in metastatic HER2+ breast cancer

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients

REVOLUÇÃO NO CANCER DE MAMA - REAÇÃO Platéia apresentação DESTINY-04

DESTINY-04: HER2 1+/FISH- Metastatic Breast Cancer TDXD Treatment | Jane Meisel, MD | ASCO22 Updates

Behind the Breakthroughs: Groundbreaking Results at ASCO 2022

Expert Report on advances in the management of HER2-negative and HER2-low advanced breast cancer

HER2+ mBC: Study Design and Results of DESTINY-Breast01

Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expression